MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm
MD 安德森癌症中心 EDRN - 使用多标记算法早期检测卵巢癌的临床验证中心
基本信息
- 批准号:10700583
- 负责人:
- 金额:$ 101.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-05 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AlgorithmsAntigensArizonaAutoantibodiesBenignBiological AssayBiological MarkersBloodBlood TestsCA-125 AntigenCTAG1 geneCancer CenterCancer DetectionClinicalCollaborationsCombination Drug TherapyComplementComplexComputer ModelsDiagnosisDiseaseEarly Detection Research NetworkEarly DiagnosisEndometrial CarcinomaEpithelial ovarian cancerEvaluationFOLR1 geneGeneral HospitalsGoalsGrantIL8 geneImageIndividualLeadLesionLinkMalignant neoplasm of ovaryMassachusettsMeasurementMeasuresOperative Surgical ProceduresOvarianOvaryPatientsPeer ReviewPelvisPlasmaPostmenopausePredictive ValuePublished CommentPublishingRecurrenceRecurrent Malignant NeoplasmRecurrent diseaseReportingResearch PersonnelRiskSamplingScreening for Ovarian CancerSecond Look SurgerySerumSiteSpecificitySpecimenTP53 geneTechnologyTestingTimeTissue SampleTissuesTumor DebulkingUltrasonographyUnited KingdomUnited StatesUniversitiesVaginaValidationWFDC2 geneWomanadvanced diseasebiomarker identificationcancer recurrencechemotherapycollaborative trialdisease heterogeneityearly detection biomarkersimprovedmortalitynovel markeroperationosteopontinpreservationrapid testroutine screeningscreeningultrasound
项目摘要
ABSTRACT: Advances in cytoreductive surgery and combination chemotherapy have improved 5-year survival
in patients with epithelial ovarian cancer, but the rate of cure remains essentially unchanged over the last two
decades. Computer models suggest that detection of ovarian cancer in early stage (I-II) could improve rates of
cure by 10-30%. In two major trials, a two-stage strategy where rising values of CA125 analyzed with a Bayesian
Risk of Ovarian Cancer Algorithm (ROCA) prompted transvaginal sonography and abnormal imaging prompted
surgery proved sufficiently specific to exceed a positive predictive value (PPV) of 10%. With support of the EDRN,
7,869 apparently healthy women have participated in the Normal Risk Ovarian Cancer Screening Study
(NROSS) at 11 different sites in the United States with 46,008 CA125 determinations over the last 21 years.
Twenty-nine patients have been referred for operations detecting 17 ovarian cancers with 12 (71%) in early stage
I or II. In addition, 4 cases of early stage endometrial cancer were detected, yielding a PPV for detecting cancer
of 72%. No more than 2-3 operations will be required to detect each case of ovarian cancer. As CA125 is
expressed by only 80% of epithelial ovarian cancers, better sensitivity is likely to be achieved with multiple
biomarkers. During this grant cycle we have reported that HE4, HE4 antigen-autoantibody complexes, and
osteopontin significantly enhance the sensitivity of CA125 for detecting early stage (I-II) disease and have
developed a ROCA2 that includes all 4 biomarkers and detects advanced disease 1.4 to 4.8 years earlier than
ROCA. We have found elevated levels of anti-TP53 autoantibodies (AA) in 20-25% of patients with ovarian
cancer. Titers of anti-TP53 rise 12 months prior to CA125 and 22 months prior to diagnosis in patients where
CA125 does not increase. In an EDRN consortium with investigators from Fred Hutchinson Cancer Center,
Arizona State University and the Massachusetts General Hospital, we have compared 5 anti-TP53 autoantibody
assays and found the RAPID assay most sensitive. Some 28 different AA have been assayed in a standard
panel of 952 sera to identify three - TP53, CTAG1, and IL-8 – that can be detected in early stage disease and
complement CA125. Over the last two decades, we have collected and preserved 922 blood and 774 tissue
samples at the time of initial surgery in patients with ovarian cancers. During the last 6.5 years we have banked
18,754 new serum and plasma samples from the NROSS and provided serum/plasma samples for 11
investigators to test biomarkers for early stage ovarian cancer. We have published 23 peer reviewed articles,
reviews and commentaries. A team of 36 investigators and staff will pursue 3 Specific Aims: 1) to conduct the
NROSS2 trial to determine the specificity and PPV of a two-stage ovarian cancer screening strategy using a 4
biomarker ROCA2 and a panel of 3 autoantibodies; 2) to evaluate multiple biomarkers for early detection of
recurrence or persistence of disease at positive second look operations; and 3) to maintain and share a serum
and plasma bank to facilitate evaluation of novel biomarkers for early detection of ovarian cancer.
摘要:细胞减少手术和联合化疗的进展提高了5年生存率
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT C BAST其他文献
ROBERT C BAST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT C BAST', 18)}}的其他基金
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
SIK2 抑制剂 GRN-300 增强卵巢癌中 PARP 抑制剂的敏感性和细胞毒性 T 细胞功能
- 批准号:
10709229 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
- 批准号:
10709227 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition
DIRAS3 破坏 K-RAS 聚类和信号传导,增强自噬和对自噬抑制的反应
- 批准号:
10707965 - 财政年份:2022
- 资助金额:
$ 101.43万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10410452 - 财政年份:2020
- 资助金额:
$ 101.43万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10226017 - 财政年份:2020
- 资助金额:
$ 101.43万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10670063 - 财政年份:2020
- 资助金额:
$ 101.43万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
9916297 - 财政年份:2020
- 资助金额:
$ 101.43万 - 项目类别:
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP
项目 4:SIK2 结合紫杉醇和 PARP 抑制剂为卵巢癌治疗提供新靶点
- 批准号:
10005298 - 财政年份:2017
- 资助金额:
$ 101.43万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 101.43万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 101.43万 - 项目类别: